SCHEMBL5261389

SCHEMBL5261389

CC(NC(=O)c1ccc(-c2ccccc2CO)cc1)C(Cc1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 16/20 0.55
CNR2 P34972 11/20 0.55
FDFT1 P37268 2/20 0.53
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ROCK2 O75116 1/20 0.45
PRKACA P17612 1/20 0.45
RPS6KB1 P23443 1/20 0.45
IRAK1 P51617 1/20 0.45
PRKX P51817 1/20 0.45
LIMK1 P53667 1/20 0.45
PRKG2 Q13237 1/20 0.45
ROCK1 Q13464 1/20 0.45
PRKG1 Q13976 1/20 0.45
PKN2 Q16513 1/20 0.45
HIPK4 Q8NE63 1/20 0.45
AURKB Q96GD4 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260787 0.87 CNR1 (0.55) CNR1CNR2FDFT1ROCK2PRKACA
SCHEMBL5260009 0.87 FDFT1 (0.68) CNR1CNR2FDFT1
SCHEMBL5263122 0.85 CNR1 (0.53) CNR1CNR2FDFT1ROCK2PRKACA
SCHEMBL5262269 0.85 CNR1 (0.63) CNR1CNR2FDFT1MEN1RAB9A
SCHEMBL5262773 0.84 CNR1 (0.72) CNR1CNR2FDFT1
SCHEMBL5263453 0.81 FDFT1 (0.59) CNR1CNR2FDFT1
SCHEMBL5261394 0.78 SMN1; SMN2 (0.48) MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL5373379 0.78 CNR1 (0.59) CNR1CNR2FDFT1
SCHEMBL5262390 0.77 CNR1 (0.59) CNR1CNR2FDFT1MEN1KMT2A
SCHEMBL5264320 0.77 CNR1 (0.66) CNR1CNR2FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494997-A4 SUBSTITUTED ARYL AMIDES MERCK & CO INC (US) 2007-04-11 EP claimed
JP-2005527586-A 2005-09-15 JP claimed
US-20050154202-A1 Substituted aryl amides MERCK & CO., INC. 2005-07-14 US claimed
EP-1494997-A1 SUBSTITUTED ARYL AMIDES Merck & Co., Inc. (US) 2005-01-12 EP claimed
WO-2003087037-A1 SUBSTITUTED ARYL AMIDES MERCK & CO., INC. (US) 2003-10-23 WO claimed
EP-1494997-A4 SUBSTITUTED ARYL AMIDES MERCK & CO INC (US) 2007-04-11 EP disclosed
US-20050154202-A1 Substituted aryl amides MERCK & CO., INC. 2005-07-14 US disclosed
EP-1494997-A1 SUBSTITUTED ARYL AMIDES Merck & Co., Inc. (US) 2005-01-12 EP disclosed
WO-2003087037-A1 SUBSTITUTED ARYL AMIDES MERCK & CO., INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154202-A1 Substituted aryl amides CNR1, CNR2, FAAH CNR1 1/4885CNR2 2/4885FDFT1 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.